Corient Private Wealth LLC Has $703,000 Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Corient Private Wealth LLC grew its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report) by 11.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,178 shares of the medical research company’s stock after acquiring an additional 220 shares during the period. Corient Private Wealth LLC’s holdings in Bio-Rad Laboratories were worth $703,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BIO. Gladius Capital Management LP increased its position in Bio-Rad Laboratories by 65.8% in the 4th quarter. Gladius Capital Management LP now owns 121 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares during the last quarter. Principal Securities Inc. bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at approximately $41,000. GAMMA Investing LLC acquired a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $42,000. Bfsg LLC bought a new position in Bio-Rad Laboratories during the fourth quarter valued at approximately $77,000. Finally, Signaturefd LLC lifted its stake in Bio-Rad Laboratories by 15.8% in the fourth quarter. Signaturefd LLC now owns 352 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 48 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BIO has been the topic of a number of recent research reports. Royal Bank of Canada cut their price target on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $315.00 price target (down previously from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $400.00 to $365.00 in a research note on Wednesday, April 3rd. UBS Group cut their price objective on Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Finally, StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Tuesday, May 28th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and an average price target of $436.67.

Read Our Latest Research Report on Bio-Rad Laboratories

Bio-Rad Laboratories Stock Performance

BIO opened at $288.42 on Wednesday. The company has a quick ratio of 4.89, a current ratio of 6.57 and a debt-to-equity ratio of 0.13. The stock’s 50 day moving average price is $296.56 and its two-hundred day moving average price is $313.38. The firm has a market capitalization of $8.23 billion, a P/E ratio of -27.84 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a 12-month low of $261.59 and a 12-month high of $431.79.

Bio-Rad Laboratories (NYSE:BIOGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.25. Bio-Rad Laboratories had a positive return on equity of 3.59% and a negative net margin of 12.37%. The company had revenue of $610.82 million during the quarter, compared to analysts’ expectations of $619.09 million. During the same period in the prior year, the business earned $3.34 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was down 9.8% compared to the same quarter last year. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.4 earnings per share for the current year.

Bio-Rad Laboratories Company Profile

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

See Also

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.